Daiichi Sankyo Co. Ltd.

Company Overview

Daiichi Sankyo is a Japan-based pharmaceutical company created in 2005 from a merger of Sankyo Co. Ltd. and Daiichi Pharmaceutical Co. Ltd. The group has 59 affiliate companies in 22 countries.

In Japan, the company is ranked the number one drug company in pharmaceutical revenue due to its extensive presence and product offerings. Daiichi Sankyo maintains a strong workforce, employing 8,648 people. The company has major research projects and product portfolios in oncology. The company is shifting its focus towards specialty drugs.

The company aims to build platform production technology that can be used efficiently to create commercial vaccines for infectious diseases such as COVID-19 and other future emerging/re-emerging infectious diseases. Its DS-5670 LNP-mRNA vaccine is delivered directly to cells by efficiently encapsulating mRNA in nanoparticles.

EXG-5003 is a self-replicating mRNA vaccine that expresses the coronavirus spike protein’s receptor binding domain (RBD). The vaccine candidate is designed with unique features for enhanced safety and dose-sparing benefits compared to other mRNA vaccines approved or in clinical trials.

Daiichi makes many new and conventional medicines to improve safety and treatment adherence. In May 2019, Daiichi launched its Minnebro tablets to treat hypertension. Minnebro is a novel, nonsteroidal, selective mineralocorticoid receptor one blocker. It was developed in research collaboration with the U.S.-based company Exelixis Inc. and was subsequently extended by Daiichi Sankyo. Daiichi recently received marketing approval for the drugs to be indicated for hypertension.

As an examination-based pharmaceutical organization, Daiichi gives answers to location-neglected therapeutic needs of patients globally. Its differing portfolio incorporates creative and generic pharmaceuticals, antibodies, and over-the-counter (OTC) medicines. Daiichi has an exceptional enthusiasm for biotech organizations and items and licenses identified with cardiovascular, oncology, and metabolic illnesses. Daiichi enhances personal satisfaction by producing inventive pharmaceuticals and using drugs to meet various medicinal needs.

Financial Highlights (FY 2024)

Company's Business Segments

• Pharmaceutical Operation : Under this segment, the company provides Oncology, Cardiovascular, Other Pharmaceuticals, and Vaccines.